Dalfampridine in Egyptian Patients With Multiple Sclerosis

Treatment tested

• Dalfampridine ER, 10 Mg Oral Tablet, Extended Release

Placebo or sham

• Placebo

Other measures (3)

Inclusion Criteria: * Age > 18 years. * Individuals diagnosed with RRMS based on revised McDonald Criteria 2017 * Patients with Expanded Disability Status Scale (EDSS) ≤ 5.5 * Patients with gait impairment according to 25 foot walk test (25FWT) with cutoff ≥ 4 seconds Exclusion Criteria: * Women who are pregnant, intended to be pregnant or breastfeeding. * Past History of epilepsy or trigeminal neuralgia. * History of any psychiatric or medical illness affecting cognition and fatigue. * Other comorbidities that might affect gait. * Clinical relapse in the last three months. * Uncooperative patients or couldn't perform the required scales. * Patients with moderate to severe depression according to patient health questionnaire (PHQ-9) with cutoff point ≥15.

The only approved treatment for impaired ambulation in MS is Dalfampridine (also known as fampridine, 4-aminopyridine, 4-AP). Fampridine penetrates the blood-brain barrier and improves impaired axonal conduction by selectively blocking potassium channels. Moreover, further studies investigated the possible beneficial effect of dalfampridine on cognitive functions and fatigue. The main objective of this study is to investigate the effect of dalfampridine on gait impairment, cognitive functions and fatigue in a sample of Egyptian patients with multiple sclerosis.